Human neutrophil migration and activation by BJcuL, a galactose binding lectin purified from Bothrops jararacussu venom.
BACKGROUND
Neutrophil migration to an inflamed site constitutes the first line of the innate immune response against invading microorganisms. Given the crucial role of endogenous lectins in neutrophil mobilization and activation, lectins from exogenous sources have often been considered as putative modulators of leukocyte function. Lectins purified from snake venom have been described as galactoside ligands that induce erythrocyte agglutination and platelet aggregation. This study evaluated human neutrophil migration and activation by C-type lectin BJcuL purified from Bothrops jararacussu venom.


RESULTS
Utilizing fluorescence microscopy, we observed that biotinylated-BJcuL was evenly distributed on the neutrophil surface, selectively inhibited by D-galactose. Lectin was able to induce modification in the neutrophil morphology in a spherical shape for a polarized observed by optical microscopy and exposure to BJcuL in a Boyden chamber assay resulted in cell migration. After 30 minutes of incubation with BJcuL we found enhanced neutrophil functions, such as respiratory burst, zymozan phagocytosis and an increase in lissosomal volume. In addition, BJcuL delays late apoptosis neutrophils.


CONCLUSIONS
These results demonstrate that BJcuL can be implicated in a wide variety of immunological functions including first-line defense against pathogens, cell trafficking and induction of the innate immune response since lectin was capable of inducing potent neutrophil activation.
Group for Advanced Molecular Investigation, PPGCS/CCBS, PUCPR, Curitiba, PR, Brazil.
Selene
S
Elifio-Esposito
Luciane
L
Tomazeli
Carolina
C
Schwartz
Ana Paula
AP
Gimenez
Gabriel M
GM
Fugii
Luiz Claudio
LC
Fernandes
Luciana F M
LF
Zishler
Patrícia M
PM
Stuelp-Campelo
Andréa N
AN
Moreno
D000818:Animals; D017837:Bothrops; D002465:Cell Movement / Q000187:drug effects* / Q000276:immunology; D003435:Crotalid Venoms / Q000737:chemistry*; D037161:Galectins / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D006801:Humans; D018375:Neutrophil Activation / Q000187:drug effects* / Q000276:immunology; D009504:Neutrophils / Q000166:cytology / Q000276:immunology*
D003435:Crotalid Venoms; D037161:Galectins
J Cell Physiol. 2002 Jun;191(3):320-6
12012327
Immunol Rev. 2003 Jun;193:101-10
12752675
J Immunol. 2002 Apr 15;168(8):4034-41
11937561
Methods. 1997 Jan;11(1):81-2
8990092
Int Arch Allergy Immunol. 2003 Nov;132(3):221-30
14646383
Curr Opin Hematol. 2010 Jan;17(1):18-24
19864946
J Biol Chem. 1990 May 15;265(14):8311-6
2186041
J Protein Chem. 2002 Jan;21(1):43-50
11902666
J Leukoc Biol. 2005 Apr;77(4):439-43
15582983
J Immunol. 1991 Apr 1;146(7):2388-93
1848582
J Leukoc Biol. 2010 Aug;88(2):321-7
20435742
Mediators Inflamm. 1995;4(4):263-9
18475649
Pathophysiol Haemost Thromb. 2005;34(4-5):150-5
16707918
Cell Mol Life Sci. 2006 Dec;63(24):3030-41
17103111
FEBS J. 2005 Dec;272(24):6179-217
16336259
J Innate Immun. 2010;2(3):216-27
20375550
EMBO J. 1999 Feb 1;18(3):501-11
9927410
Blood. 2003 Oct 1;102(7):2660-9
12829592
Curr Opin Hematol. 2010 Jan;17(1):9-17
19864945
Toxicon. 2006 Jan;47(1):21-31
16309723
Ann Hematol. 2000 Feb;79(2):83-5
10741920
J Leukoc Biol. 2005 Jun;77(6):886-92
15728244
Rev Immunogenet. 2000;2(3):339-58
11256744
J Leukoc Biol. 2004 Mar;75(3):467-77
14673018
Anticancer Res. 2001 Sep-Oct;21(5):3453-6
11848508
Annu Rev Biochem. 1986;55:35-67
3527046
Ann Hematol. 1995 May;70(5):259-65
7599287